As technology reshapes the way we live and work, trade secrets have become very important. They have unleashed an unprecedented boom in litigation, legislation and media attention. And some investors and companies have found themselves in court or facing damages in the hundreds of millions of dollars. “Trade secrets are the hardest form of IP to…

In this article published in Law360, Rimon’s CEO Michael Moradzadeh argues that allowing lawyers to work remotely can be counterproductive if the firm’s entire model and culture does not ensure that telecommuters are equally connected to the firm’s social and professional communities. “To take full advantage of the enormous potential of the cloud, law firms must thoughtfully…

New York – Joseph I. Rosenbaum, a leading nationally and internationally recognized commercial lawyer, has joined Rimon Law as a Partner in its New York office.  Mr. Rosenbaum joins Rimon from Reed Smith where he was previously a partner. Mr. Rosenbaum represents major multinational companies, emerging growth businesses, as well as small to medium size…

Rimon Partner John Isaza, head of information governance and records management practices, believes that the unlawful access to taxpayers’ prior-year tax return through the app ‘Get Transcript’ is not necessarily a data breach.  ‘It’s more an issue of taking the hacking to the next level,’ he says.  They’ve been collecting all this data by hacking…

So how do biotech ventures govern themselves to run efficiently while complying with state corporate law statutes and state and federal securities laws and regulations imposed by stock exchanges? Frugality that is often self-imposed by scientific founders and then endorsed by the angel investors and venture capital company investors that follow sequentially tend to result…

The public securities markets and the underwriters that lead biotech companies into them dictate a common capital structure suitable for IPOs, which structure almost always deviates starkly from the capital structure of the venture at inception and during its growth phase. Startups frequently commence corporate life structured as limited liability companies with a few founders…

Mindful that this series of articles describes biotech ventures that are ripe for initial public offerings even before launching an income-producing drug product into the commercial market, the paramount objective for all such ventures is to manufacture drugs and commence marketing, sales and distribution thereof as soon as possible. As you read in the previous…

Furthering its reputation for innovation and as a leader in intellectual property protection in Silicon Valley, Rimon is pleased to announce the addition of Robert H. Lee as its Technologist-in-Residence. He is also Research Fellow in Law, Science & Technology at Stanford University. Mr. Lee focuses on intellectual property protection, angel and VC financing and…

For a drug discovery start-up, patent protection of the intellectual property underlying the commercialization pursuit is critically important. If the company is a university or research institution spin-out that obtained licensed rights to intellectual property through a technology transfer, either the licensor or the licensee – as set forth in the License Agreement — must pursue…

The U.S. Food & Drug Administration regulates new drug approvals in a process that is extremely thorough, lengthy and expensive. Regulations apply to a drug candidate’s product development phase, the approval process and after approval. Failure to comply could have serious business and financial con-sequences to a biotech venture, including the FDA’s refusal to approve…